PerkinElmer is expanding its Horizon Discovery CHOSOURCE platform to include a new expression cell line, CHO-K1 ADCC+, which may improve potency and efficacy of therapeutic antibodies and fusion protein biotherapeutics, as well as reduce dosage requirements and side effects for patients.
This new expression host was built from Horizon’s biomanufacturing cell line, CHO-K1 GS KO, by removing the fucose gene to increase antibody-dependant cellular cytotoxicity (ADCC) activity.
The use of afucosylated antibodies and fusion proteins is expanding from oncology applications to infectious diseases like flu, Ebola, SARS and Covid-19, and most recently, autoimmune conditions. The availability of production tools, like the CHO-K1 ADCC+ cell line, enables companies to develop treatments across broader indications.
The CHOSOURCE platform, now with CHO GS-KO and ADCC+ expression cell lines, is easily adaptable for implementation in proprietary biomanufacturing processes in the early stages of discovery and development of therapeutic programmes.
“Horizon has a long track-record in gene editing technologies that enable us to expand our CHOSOURCE platform to offer global scientists new and improved expression cell lines and service offerings to meet their evolving biotherapeutic development needs,” said Jesus Zurdo, head of cell and gene therapy and bioproduction for Horizon, a PerkinElmer company. “We are extremely excited about this new addition to the CHOSOURCE family which we will continue to add to in the future.”
